What does Revuforj (Revumenib) do and do?

Revuforj (Revumenib) is a targeted therapy drug for acute leukemia that mainly exerts its efficacy by acting on the scaffold protein menin. Menin is a protein that plays an important regulatory role in cells, especially in the occurrence and development of leukemia. Revumenib can effectively block the interaction between menin and wild-type and rearranged KMT2A (lysine transferase 2A), thereby downregulating the transcription pathway leading to leukemia.

KMT2A rearrangement is a common mutation form in acute leukemia. The production of KMT2A fusion protein activates the related leukemogenic transcription pathway, leading to the arrest of proliferation and differentiation of leukemia cells. Revumenib blocks the transmission of these pathogenic signals by destroying the binding of this fusion protein to menin, thereby promoting the maturation and differentiation of leukemia cells and inhibiting their proliferation. This mechanism provides a new treatment idea for patients with acute leukemia, especially for those patients carrying KMT2A rearrangements. Revumenib has shown significant anti-tumor activity.

In non-clinical studies,Revumenib has demonstrated good anti-proliferative effects. In vitro and in vivo experiments show that the drug can effectively inhibit the growth of leukemia cells containing KMT2A fusion protein and change the transcription levels of a variety of differentiation-related genes. These research results not only prove the targeting effect of Revumenib, but also provide evidence for its potential in clinical application.

In addition,The relationship between the dose and effect of Revumenib is still under further study. Although the existing data supports the effectiveness and safety of this drug at appropriate doses, more clinical data are still needed to verify its optimal use and long-term effects. When using Revumenib, special attention needs to be paid to changes in the QTc interval. This is because Revumenib can cause QTc prolongation, especially when used concomitantly with other drugs that may cause QTc prolongation. Therefore, when patients receive this treatment, doctors need to closely monitor the electrocardiogram and adjust the treatment plan according to the actual situation.

Reference materials:https://go.drugbank.com/drugs/DB18515